The Week in Review #31
IN THE DEPARTED WEEK
NOVEL MIGRAINE DRUGS ARE APPROVED
ELI LILLY AFTER AMGEN AND TEVA
In less than five months, the FDA approved three products belonging to four drug developers – all
targeting calcitonin gene-related peptide (CGRP) for the prevention of migraine headache. The
latest for Eli Lilly (LLY) last week . . .
This content is for paid subscribers.
Prohost Letters
October 2, 2018
